Medicinal Chemistry Integration
Modern drug discovery is a multi-disciplinary team effort for creating small molecules as well as more complex modalities such as dual-target small molecules, protein degraders, or cyclopeptides. A skilled chemistry team is the main driver for developing new chemical entities to create new IP and value for our customers. The Reaction Oncology Platform enables a team approach by bringing together highly skilled chemists and our experienced biologists.
Our clients get access to premium chemistry via our partner Symeres. Being Europe‘s best-in-class chemistry provider, Symeres has a stunning track record of successfully creating new APIs used daily in clinics worldwide. Symeres excels in creativity and has over 30 years of chemistry experience to deliver novel small molecules tackling even the most challenging targets.
We have collaborated with Symeres since 2012 on several small molecule oncology programs. Our teams work together seamlessly under one MSA. We take responsibility for all logistical aspects of the project (compound registration and shipping, screening logistics, tracking of stock quantities, etc.), allowing our client to fully focus on the science.
Medinoah is our Chinese chemistry partner with track records of AI modeling, discovery, and cGMP production in the small molecule and PROTAC space. The company was founded in 2008 and has already promoted more than 20 compounds into IND/clinical stages.
As one of the earliest medicinal chemistry providers entering the PROTAC field, Medinoah provides libraries for ligases and linkers to fast-track new PROTAC molecule development. Their access to artificial development resources enables the prediction of binding modes of compounds and targets, reducing the number of screening cycles needed to generate potent and optimized compounds.